Quincy Bioscience: The Prevagen Memory Supplement Maker Whose Clinical Trial Showed the Product Did Not Work

Quincy Bioscience LLC, the manufacturer of Prevagen — a brain health supplement marketed specifically to older adults concerned about age-related memory decline — agreed to a settlement resolving charges that it made deceptive claims about the supplement's ability to improve memory and cognitive function while the company's own double-blind, placebo-controlled clinical trial of the product found that it performed no better than a placebo on the primary cognitive measures the product was sold to address.DOCUMENTED

Prevagen is one of the top-selling brain health supplements in the United States, marketed extensively through television advertising, pharmacy placement, and direct-to-consumer digital campaigns. The supplement's active ingredient is apoaequorin, a protein derived from jellyfish, which Quincy Bioscience marketed as having specific memory-supporting properties. The product's advertising featured claims like "improves memory" and "supports healthier brain function" alongside references to clinical testing that, regulators found, described the clinical evidence in ways that were materially misleading given the actual findings of the company's study.DOCUMENTED

The Madison Memory Study

Quincy Bioscience funded and conducted the Madison Memory Study, a randomized, double-blind, placebo-controlled trial in which participants were randomly assigned to receive either Prevagen or a placebo and completed cognitive tests at the beginning and end of the study period. The gold standard of clinical evidence for evaluating a health product's efficacy is exactly this type of trial, because it controls for placebo effects and for the natural variation in performance that participants show when tested multiple times.REVIEWED

The primary analysis of the Madison Memory Study — the pre-specified, primary endpoint analysis that is the study's main test of the hypothesis that Prevagen improves memory — found no statistically significant difference between the Prevagen group and the placebo group on the cognitive measures administered. In other words, the trial's main finding was that Prevagen did not perform better than a placebo when the study was analyzed as designed and pre-specified. A product that fails to outperform a placebo in a well-designed clinical trial has not demonstrated efficacy for the tested measures.DOCUMENTED

The Subgroup Analysis Problem

Rather than accepting the primary analysis finding — which would have required Quincy Bioscience to either abandon its memory improvement claims or conduct further research supporting them — the company relied on subgroup analyses of the Madison Memory Study data to support its advertising claims. Subgroup analysis involves breaking the study population into smaller groups and analyzing whether the intervention worked better in some groups than others — for example, whether participants who started with lower cognitive scores showed a larger benefit from Prevagen than the full study population.REVIEWED

Subgroup analyses that were not pre-specified before data collection are considered exploratory rather than confirmatory evidence — they can generate hypotheses for future research but cannot reliably be used to make marketing claims about a product's efficacy. The reason is well-established in clinical research methodology: if you analyze enough subgroups, you will eventually find some that show a statistically significant difference by chance, even when the intervention has no real effect. A company that cherry-picks favorable subgroup findings from a failed primary analysis to support marketing claims is presenting the clinical evidence in a way that is fundamentally misleading about what the research actually shows.DOCUMENTED

The Madison Memory Study — Quincy Bioscience's own clinical trial — found no significant difference between Prevagen and placebo in its primary analysis. The company then used favorable subgroup analyses from the same failed trial to continue marketing the product as clinically proven to improve memory.

Supplement Advertising and the Older Adult Market

Brain health supplements are a multibillion-dollar market category that targets older adults who are concerned about age-related cognitive changes — a demographic that is particularly motivated to find products that can help maintain or improve their cognitive function. The marketing vulnerability of this population is significant: older adults who are genuinely experiencing memory concerns may invest in supplement products at substantial cost, based on advertising claims that appeal directly to their concerns, without being able to independently evaluate the clinical evidence underlying those claims.REVIEWED

The Prevagen case illustrates the gap between what dietary supplement manufacturers are required to prove before making structure-function health claims on their products and what the scientific evidence actually demonstrates. Dietary supplements in the United States are not required to demonstrate efficacy before reaching the market — manufacturers bear the responsibility for ensuring claims are substantiated, but there is no pre-market review of that substantiation by regulators. When the substantiation is inadequate or misleading, enforcement after the fact — as in the Prevagen case — is the primary mechanism for protecting consumers.REVIEWED

Settlement Requirements

The settlement requires Quincy Bioscience to have competent and reliable scientific evidence — defined as at least one well-designed, randomized, controlled trial demonstrating a statistically significant benefit on the pre-specified primary endpoint — before making claims that Prevagen or any future product specifically improves memory or cognitive function. The company is prohibited from characterizing subgroup analyses from a failed primary trial as clinical proof of efficacy. Consumers who purchased Prevagen based on its memory improvement advertising should be aware of the settlement's findings about the clinical evidence and may wish to consult a healthcare provider about the evidence base for any brain health supplement they are considering.DOCUMENTED

Evaluating Brain Health Supplement Claims

Consumers who are considering any brain health or memory supplement should apply the same standard that clinical researchers use to evaluate efficacy claims: ask whether the evidence consists of a well-designed, randomized, placebo-controlled trial that found a statistically significant improvement on a pre-specified primary endpoint. That standard — not testimonials, not company-funded observational studies, not subgroup analyses from failed trials — is the minimum threshold for a legitimate claim that a supplement improves cognitive function. The vast majority of marketed brain health supplements do not meet this evidentiary standard. The Prevagen case is instructive because the company had actually conducted a clinical trial — a step many supplement companies skip entirely — and the trial still found no significant benefit on its primary measure. Consumers who want to maintain or improve cognitive function should consult with their physician about evidence-based approaches including management of cardiovascular risk factors, sleep quality, physical activity, and social engagement, all of which have stronger evidence bases than any currently marketed brain health supplement.

Have documents relevant to this story? Reach us through our tips channel.